Egetis Therapeutics AB is a unique pharmaceutical company that specializes in the development of late-stage projects for the treatment of serious rare diseases with significant unmet medical needs in the orphan drug segment. Their innovative approach aims to address the specific challenges faced by patients with these conditions, providing much-needed treatment options. With a focus on commercialization, Egetis is dedicated to bringing their late-stage projects to market and improving the lives of those affected by these diseases.